Silverarc Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-100,000
| Closed | -$1.92M | – | 79 |
|
|
2024
Q4 | $1.92M | Buy |
+100,000
| New | +$1.92M | 0.42% | 44 |
|
|
2024
Q1 | – | Sell |
-50,438
| Closed | -$1.1M | – | 93 |
|
|
2023
Q4 | $1.1M | Buy |
50,438
+3,000
| +6% | +$65.3K | 0.33% | 57 |
|
|
2023
Q3 | $728K | Buy |
47,438
+2,438
| +5% | +$37.4K | 0.22% | 56 |
|
|
2023
Q2 | $1.07M | Buy |
45,000
+8,619
| +24% | +$205K | 0.33% | 53 |
|
|
2023
Q1 | $926K | Buy |
36,381
+33,381
| +1,113% | +$849K | 0.38% | 54 |
|
|
2022
Q4 | $87.6K | Buy |
+3,000
| New | +$87.6K | 0.03% | 78 |
|
|
2022
Q2 | – | Sell |
-126,136
| Closed | -$2.33K | – | 75 |
|
|
2022
Q1 | $2.33K | Buy |
126,136
+2,330
| +2% | +$43 | 0.97% | 26 |
|
|
2021
Q4 | $2.45M | Buy |
123,806
+17,728
| +17% | +$351K | 0.99% | 32 |
|
|
2021
Q3 | $1.75M | Buy |
106,078
+77,679
| +274% | +$1.28M | 0.99% | 36 |
|
|
2021
Q2 | $519 | Buy |
28,399
+813
| +3% | +$15 | 0.23% | 76 |
|
|
2021
Q1 | $461K | Buy |
+27,586
| New | +$461K | 0.25% | 71 |
|